Sale! LEVIGON

LEVIGON

Sanitpharma

923544011

New

Supplement, Powder for oral solution - Fast formulation, 20 sticks                                                   Italian Pharmacode: 923544011.

More details

Buy product


More info

Levigon is a food supplement in a fast dissolving form containing Myo-inositol, Liposomal-Magnesium and Folic Acid. Levigon can help getting an adequate dietary amount in case of low intake or increased need of these elements.

  • Myo-inositol: natural compound known to possess insulin-mimetic properties and to improve insulin resistance. It is characterized by a very good safety profile and it is naturally present in a variety of foods particularly in beans, grains, nuts and fruits (oranges and melon).
  • Liposomal-Magnesium: Liposomal technology encapsulates magnesium into a lipid- based molecule and guarantees optimal absorption through the digestive system. Several recent studies showed that oral magnesium supplementation results in a significant improvement of fasting plasma glucose and insulin sensitivity.
  • Folic Acid: treats the inability of the GI to absorb nutrients properly. In pregnant women prevents neural tube defects of the newborn. Several studies showed that folic acid has an improving effect on insulin resistance and reduces the circulating level of some inflammatory mediators.

How to use
We recommend one or two sticks of oral soluble granules a day. If desired Levigon can be diluted in water.



References

Gelfand JM, Yeung H., Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012 Jul;89:24-8.

Au SC, Goldminz AM, Loo DS, Dumont N, Levine D, Volf E, Michelon M, Wang A, Kim N, Yaniv S, Lizzul PF, Kerensky T, Lopez-Benitez JM, Natter M, Miller L, Pelajo CF, Davis T, Gottlieb AB., Association between pediatric psoriasis and the metabolic syndrome. J. Am Acad Dermatol. 2012 Jun;66(6):1012-3.

Matarrelli B, Vitacolonna E, D'angelo M, Pavone G, Mattei PA, Liberati M, Celentano C., Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013 Mar 1.

Boehncke WH, Boehncke S, Buerger C., Beyond immunopathogenesis. Insulin resistance and "epidermal dysfunction". Hautarzt. 2012 Mar;63(3):178-83.

Del Prete M, Mauriello MC, Faggiano A, Di Somma C, Monfrecola G, Fabbrocini G, Colao A., Insulin resistance and acne: a new risk factor for men? Endocrine. 2012 Dec;42(3):555-60.

Mumcuoglu C, Ekmekci TR, Ucak S., The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011 Jan-Feb;21(1):79-82.

Jucci A, Vignini M, Pelfini C, Criffŏ A, Fratino P., Psoriasis and insulin secretion. Preliminary results. Arch Dermatol Res. 1977 Jan 31;257(3):239-46.

Moro F, De Simone C, Morciano A, Tropea A, Sagnella F, Palla C, Scarinci E, Teti A, Caldarola G, D'Agostino M, Mancuso S, Lanzone A, Apa R., Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertil Steril. 2012 Nov 16.

Piérard-franchimont C, Quatresooz P, Piérard GE, Scheen AJ., The psoriasis--metabolic syndrome comorbidity, a complex multigenic disease. Rev Med Liege. 2012 May-Jun;67(5-6):337-40.

Karadag AS, Ertugrul DT, Bilgili SG, Takci Z, Tutal E, Yilmaz H., Insulin resistance is increased in alopecia areata patients. Cutan Ocul Toxicol. 2013 Jun;32(2):102-6.

Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G., Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res. 2012 Apr;15(2):217-21.

Condorelli RA, La Vignera S, Bellanca S, Vicari E, Calogero AE., Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012 Jun;79(6):1290-5.

Colone M, Marelli G, Unfer V, Bozzuto G, Molinari A, Stringaro A., Inositol activity in oligoasthenoteratospermia--an in vitro study. Eur Rev Med Pharmacol Sci. 2010 Oct;14(10):891-6.

Gelber D, Levine J, Belmaker RH., Effect of inositol on bulimia nervosa and binge eating. Int J Eat Disord. 2001 Apr;29(3):345-8.

Munekage E, Takezaki Y, Hanazaki K., Shortage and metabolic disturbance of magnesium in diabetic patients and significance of magnesium replacement therapy. Clin Calcium. 2012 Aug;22(8):1235-42.

Volpe SL., Magnesium, the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus. Crit Rev Food Sci Nutr. 2008 Mar;48(3):293-300. 


Notes

Patented fast formulation

Accept

This site uses cookies to improve your experience.
By using this site or closing this message you are agreeing to our Cookie Policy.